# Q32 Bio

Q32 Bio is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Assets under management:** Undisclosed
- **Website:** q32bio.com
- **LinkedIn:** https://www.linkedin.com/company/q32-bio-inc

## Regulatory record

- **Reports private funds:** No

## About

Q32 Bio is developing drugs targeting powerful regulators of both the innate and adaptive immune systems with the goal of re-balancing the immune system.

## Sectors

- Healthcare Services

## Questions

### What is Q32 Bio's lead clinical program?

The firm's most advanced candidate is bempikibart, a fully human anti-IL-7Rα monoclonal antibody. It is currently being evaluated in a Phase 2 trial for alopecia areata. The molecule blocks signaling of both IL-7 and thymic stromal lymphopoietin (TSLP), two cytokines that regulate adaptive immune function.

### How does bempikibart's mechanism differ from other autoimmune therapies?

Bempikibart targets the IL-7 receptor alpha chain, simultaneously inhibiting IL-7 and TSLP signaling. This dual blockade is designed to re-regulate T-cell-driven inflammation upstream of many current targets. Most approved autoimmune drugs, such as JAK inhibitors, act further downstream or on different cytokine families.

### Has Q32 Bio disclosed any capital raised or investors?

No. As of its most recent public disclosures available in mid-2026, the firm has not published a fundraising total, named any institutional investors, or confirmed a cash runway. Financial details remain entirely undisclosed.

### What is the market context for alopecia areata treatments?

As of 2025, there are zero FDA-approved therapies for alopecia areata, though late-stage JAK inhibitor programs from other companies have generated significant clinical data. An estimated 700,000 people in the United States live with the disease, creating a substantial commercial opportunity for any therapy that demonstrates disease-modifying efficacy with an acceptable safety profile.

### Does Q32 Bio have any other pipeline assets beyond bempikibart?

The company's public-facing materials reference only a single program targeting autoimmune and inflammatory diseases. There is no disclosure of preclinical assets, technology platform licenses, or combination approaches.

## Related profiles

- [GEHA Ventures](https://altss.com/profile/geha-ventures)
- [Modular Asset Management](https://altss.com/profile/modular-asset-management)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/q32-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology